23J Stock Chart & Stats
€10.60
-€1.10(-9.40%)
At close: 4:00 PM EDT
€10.60
-€1.10(-9.40%)
Day’s Range― - ―
52-Week Range€5.68 - €22.00
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€106.69M
Enterprise Value€19.05
Total Cash (Recent Filing)€63.85M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta0.24
Next Earnings
Aug 13, 2026EPS Estimate
-1.2Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-23.59
Shares Outstanding8,967,693
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-9.53K
Price to Sales (P/S)0.00
P/FCF Ratio-426.74
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€31.19Price Target Upside194.28% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-4.64
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Progress: PMN310 Interim Safety & BiomarkersBlinded interim data showing favorable safety across genotypes, no ARIA‑E, and early biomarker reductions materially de‑risks PMN310's clinical profile. Over 2–6 months this strengthens the program's chance to reach unblinded efficacy readouts and attracts partners, underwriting longer‑term development and partnership optionality.
Low Leverage And Meaningful Equity BaseA no‑debt balance sheet with a meaningful equity cushion lowers financial risk and preserves flexibility to fund near‑term R&D without interest burden. Structurally, this supports continuity of clinical programs and gives the company negotiating leverage with potential collaborators over the medium term.
Oligomer-selective Antibody PlatformThe oligomer‑selective approach targets pathogenic conformations rather than plaques, addressing a key limitation of existing therapies (ARIA risk). This differentiated mechanism is a durable competitive advantage, supporting pipeline breadth, potential label differentiation, and longer‑term licensing or partnership value across neurodegenerative indications.
Bears Say
Pre-revenue With Heavy Cash BurnAs a pre‑revenue biotech, PMN runs sizable recurring losses and negative operating/free cash flow, necessitating external capital. Over months this cash burn constrains runway, raises execution risk for trials, and increases the likelihood of dilutive financings if non‑dilutive partnerships or milestone inflows do not materialize.
Inconsistent Equity Position HistoricallyPeriods of negative equity indicate balance‑sheet volatility and past capital strain. This structural instability can weaken investor and partner confidence, elevate the perceived cost of capital, and complicate long‑term planning and contract negotiations for non‑dilutive funding or strategic alliances.
Reliance On Financings And Dilution RiskThe business model depends on equity financings and incentive share reserves to fund operations and retain talent. Structurally, recurring reliance on equity and expanded compensation capacity implies persistent dilution risk, which can erode shareholder value over time absent milestone success or significant non‑dilutive partnership revenues.
ProMIS Neurosciences News
23J FAQ
What was ProMIS Neurosciences’s price range in the past 12 months?
ProMIS Neurosciences lowest stock price was €5.68 and its highest was €22.00 in the past 12 months.
What is ProMIS Neurosciences’s market cap?
ProMIS Neurosciences’s market cap is €106.69M.
When is ProMIS Neurosciences’s upcoming earnings report date?
ProMIS Neurosciences’s upcoming earnings report date is Aug 13, 2026 which is in 6 days.
How were ProMIS Neurosciences’s earnings last quarter?
ProMIS Neurosciences released its earnings results on May 12, 2026. The company reported -€1.093 earnings per share for the quarter, missing the consensus estimate of -€0.919 by -€0.173.
Is ProMIS Neurosciences overvalued?
According to Wall Street analysts ProMIS Neurosciences’s price is currently Undervalued.
Does ProMIS Neurosciences pay dividends?
ProMIS Neurosciences does not currently pay dividends.
What is ProMIS Neurosciences’s EPS estimate?
ProMIS Neurosciences’s EPS estimate is -1.2.
How many shares outstanding does ProMIS Neurosciences have?
ProMIS Neurosciences has 8,967,693 shares outstanding.
What happened to ProMIS Neurosciences’s price movement after its last earnings report?
ProMIS Neurosciences reported an EPS of -€1.093 in its last earnings report, missing expectations of -€0.919. Following the earnings report the stock price went up 10.256%.
Which hedge fund is a major shareholder of ProMIS Neurosciences?
Currently, no hedge funds are holding shares in DE:23J
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
ProMIS Neurosciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€31.19 (194.28% Upside)
€31.19 (194.28% Upside)
Blogger Sentiment
Bullish
DE:23J Sentiment 100%
Sector Average ―
Sector Average ―
Technicals
SMA
Positive
20 days / 200 days
Momentum
-46.13%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
393.98%
Trailing 12-Months
Company Description
ProMIS Neurosciences
ProMIS Neurosciences, Inc. is a Canadian biotechnology firm dedicated to creating targeted therapeutic solutions for debilitating neurodegenerative conditions such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company leverages a unique computational discovery platform, utilizing its ProMIS and Collective Coordinates algorithms, to identify novel, disease-specific targets – known as epitopes – located on the surface of misfolded proteins. Its pipeline features several promising drug candidates, including PMN310, a monoclonal antibody designed to address toxic oligomers implicated in Alzheimer's disease. Another candidate, PMN267, targets superoxide dismutase 1 and TAR-DNA binding protein 43 in ALS, and alpha-synuclein associated with Parkinson's disease and Lewy body dementia. Finally, PMN442 is a monoclonal antibody aimed at toxic alpha-synuclein oligomers and seeding fibrils relevant to multiple system atrophy. Established in 2004, the company changed its name from Amorfix Life Sciences Ltd. to ProMIS Neurosciences, Inc. in July 2015. Its corporate headquarters are situated in Toronto, Canada.
23J Stock 12 Month Forecast
Average Price Target
€31.19
▲(194.28% Upside)